Loading
PTGS1 (Prostaglandin G/H synthase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes. This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.93, animal model 0.64, genetic association 0.37, clinical 0.88).
In plain words · PTGS1 (Prostaglandin G/H synthase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
PTGS1 (Prostaglandin G/H synthase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response.
No product in this corpus aims at PTGS1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PTGS1: RNA tissue enhanced (intestine 102 nTPM, skin 1 144 nTPM, urinary bladder 228 nTPM); blood lineage group enriched (dendritic cells 20 nTPM, granulocytes 29 nTPM, monocytes 13 nTPM); high antibody staining in 10 normal tissues; highest cancer staining ovarian cancer (7 of 12 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas PTGS1 tissue; Open Targets ENSG00000095303 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Yokoyama et al, Biochem. Biophys. Res. Commun, 1989, "Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme". Source.
Sources: HGNC HGNC:9604 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P23219 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000095303 (association with cancer (MONDO_0004992) 0.62; (GraphQL API, CC0))
Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes. This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. Location: Microsome membrane; Endoplasmic reticulum membrane (UniProt). Locus 9q33.2 (HGNC).
RNA: tissue enhanced (intestine 102 nTPM, skin 1 144 nTPM, urinary bladder 228 nTPM), detected in many normal tissues. Blood: group enriched (dendritic cells 20 nTPM, granulocytes 29 nTPM, monocytes 13 nTPM).
Medium: Bone marrow, Caudate, Cerebellum, Cerebral cortex, Cervix, Esophagus, Hippocampus, Lymph node.
RNA cancer enhanced: Ovary Serous Cystadenocarcinoma 86 pTPM.
Medium only: breast cancer, cervical cancer, colorectal cancer, glioma.
HPA PTGS1 tissue · HPA PTGS1 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PTGS1" OR ABSTRACT:"PTGS1" OR TITLE:"prostaglandin-endoperoxide synthase 1" OR ABSTRACT:"prostaglandin-endoperoxide synthase 1" OR TITLE:"Prostaglandin G/H synthase 1" OR ABSTRACT:"Prostaglandin G/H synthase 1" OR TITLE:"COX1" OR ABSTRACT:"COX1" OR TITLE:"PGHS-1" OR ABSTRACT:"PGHS-1" OR TITLE:"PTGHS" OR ABSTRACT:"PTGHS") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTGS1, not a curated reading list.